CA2151742C - Compositions pour l'administration d'agents actifs par voie orale - Google Patents

Compositions pour l'administration d'agents actifs par voie orale

Info

Publication number
CA2151742C
CA2151742C CA002151742A CA2151742A CA2151742C CA 2151742 C CA2151742 C CA 2151742C CA 002151742 A CA002151742 A CA 002151742A CA 2151742 A CA2151742 A CA 2151742A CA 2151742 C CA2151742 C CA 2151742C
Authority
CA
Canada
Prior art keywords
composition
carrier particle
binding moiety
binding
active agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002151742A
Other languages
English (en)
Other versions
CA2151742A1 (fr
Inventor
Alfred A. Amkraut
Heechung Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of CA2151742A1 publication Critical patent/CA2151742A1/fr
Application granted granted Critical
Publication of CA2151742C publication Critical patent/CA2151742C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6933—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Abstract

Compositions et procédés destinés à l'administration orale de médicaments et d'autres principes actifs. Ces compositions comprennent une particule de transport d'agent actif fixée à une fraction de liaison qui se lie spécifiquement à une molécule cible présente sur la surface d'un entérocyte de mammifère. La fraction de laiaison se lie à la molécule cible avec une affinité ou une avidité de liaison suffisante pour amorcer l'endocytose ou la phagocytose de la particule de transport d'agent actif, de sorte que cette dernière va être absorbée par l'entérocyte. L'agent actif sera ensuite libéré de la particule de transport dans la circulation systémique de l'hôte. De cette manière, on évite la dégradation de médicaments sensibles à la dégradation, tels que les polypeptides, dans l'intestin, tout en augmentant l'absorption de protéines et de polypeptides à partir du tractus intestinal.
CA002151742A 1993-02-22 1994-02-22 Compositions pour l'administration d'agents actifs par voie orale Expired - Fee Related CA2151742C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2048193A 1993-02-22 1993-02-22
US08/020,481 1993-02-22
PCT/US1994/001756 WO1994018955A1 (fr) 1993-02-22 1994-02-22 Compositions destinees a l'apport oral d'agents actifs

Publications (2)

Publication Number Publication Date
CA2151742A1 CA2151742A1 (fr) 1994-09-01
CA2151742C true CA2151742C (fr) 1999-05-25

Family

ID=21798853

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002151742A Expired - Fee Related CA2151742C (fr) 1993-02-22 1994-02-22 Compositions pour l'administration d'agents actifs par voie orale

Country Status (9)

Country Link
US (2) US5620708A (fr)
EP (1) EP0684814B1 (fr)
JP (1) JPH08507070A (fr)
AT (1) ATE167396T1 (fr)
AU (1) AU6268894A (fr)
CA (1) CA2151742C (fr)
DE (1) DE69411154T2 (fr)
MX (1) MX9401351A (fr)
WO (1) WO1994018955A1 (fr)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344213B1 (en) * 1996-03-29 2002-02-05 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO1996013250A1 (fr) * 1994-10-27 1996-05-09 Amgem Inc. Compositions pour une assimilabilite accrue d'agents therapeutiques administres par voie orale
WO1996020698A2 (fr) * 1995-01-05 1996-07-11 The Board Of Regents Acting For And On Behalf Of The University Of Michigan Nanoparticules a modification de surface et leurs procedes de fabrication et d'utilisation
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
CA2252438C (fr) * 1996-04-19 2011-03-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine Intimine marquee a l'histidine et procedes d'utilisation de l'intimine pour stimuler une reaction immunitaire et en tant que porteur d'antigene a capacite de ciblage
US6143037A (en) * 1996-06-12 2000-11-07 The Regents Of The University Of Michigan Compositions and methods for coating medical devices
US6361938B1 (en) * 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
JP4203159B2 (ja) * 1997-12-09 2008-12-24 株式会社林原生物化学研究所 神経機能調節剤
US6355270B1 (en) * 1999-01-11 2002-03-12 The Regents Of The University Of California Particles for oral delivery of peptides and proteins
AU5721900A (en) * 1999-03-08 2000-09-28 Lockheed Martin Corporation Single-pass interferometric synthetic aperture radar
US8383081B2 (en) 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US8119101B2 (en) * 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
US7829064B2 (en) * 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
EP1229924A4 (fr) * 1999-11-19 2004-12-15 Univ Leland Stanford Junior Molecules bifonctionnelles ciblees et therapies basees sur celles-ci
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US6537968B1 (en) * 2000-07-24 2003-03-25 Alphamed Pharmaceuticals Corp Treatment of lupus erythematosus
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
KR101320817B1 (ko) * 2001-06-01 2013-10-21 노파르티스 아게 부갑상선 호르몬 및 칼시토닌의 경구 투여
ES2304467T3 (es) * 2001-07-10 2008-10-16 North Carolina State University Vehiculo de liberacion de nanoparticulas.
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
AU2003273272A1 (en) * 2002-06-03 2003-12-19 Alinis Biosciences, Inc. Therapeutic agent-containing polymeric nanoarticles
US20050129769A1 (en) * 2002-06-03 2005-06-16 Barry Stephen E. Polymeric articles for carrying therapeutic agents
NZ538284A (en) 2002-07-18 2008-04-30 Helix Biopharma Corp Use of urease and targeting molecule for inhibiting cancer cell growth
EP1551876B1 (fr) 2002-10-16 2011-03-16 Purdue Pharma L.P. Anticorps se fixant sur des polypeptides ca 125/0722p associes a des cellules et leurs procedes d'utilisation
JP2006524036A (ja) 2002-11-08 2006-10-26 アブリンクス エン．ヴェー． 腫瘍壊死因子αを標的とする単一ドメイン抗体およびその使用
WO2005044858A1 (fr) 2003-11-07 2005-05-19 Ablynx N.V. Polypeptide vhh de camelidae, anticorps a domaine unique diriges contre le recepteur de facteur de croissance epidermique et utilisations de ceux-ci
AU2003286003B2 (en) 2002-11-08 2011-05-26 Ablynx N.V. Stabilized single domain antibodies
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
WO2004066975A1 (fr) * 2002-12-18 2004-08-12 Hough Ear Institute Nanotechnologie otologique
AU2004204763A1 (en) * 2003-01-09 2004-07-29 Arizeke Pharmaceuticals Inc. Compositions and methods for targeted biological delivery of molecular carriers
EP2390270A1 (fr) 2003-01-10 2011-11-30 Ablynx N.V. Polypeptides thérapeutiques, leurs homologues, leurs fragments et leur utilisation pour la modulation de l'agrégation de plaquettes
EP1610752B1 (fr) * 2003-01-31 2013-01-02 Boston Scientific Limited Distribution localisee d'un medicament au moyen de nanocapsules chargees de medicament et dispositif implantable revetû de celles-ci
US20110171126A1 (en) * 2010-01-11 2011-07-14 Center For Molecular Medicine And Immunology Enhanced Cytotoxicity of Anti-CD74 and Anti-HLA-DR Antibodies with Interferon-Gamma
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US8883160B2 (en) * 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
ES2357606T3 (es) 2004-04-15 2011-04-28 Athera Biotechnologies Ab Anticuerpos contra conjugados de fosforilcolina.
JP2007535546A (ja) * 2004-04-29 2007-12-06 グラクソスミスクライン・イストラジヴァッキ・センタル・ザグレブ・ドルズバ・ゼー・オメイェノ・オドゴヴォルノスティオ 代謝性骨疾患を処置するための骨形成タンパク質を含む経口製剤
US7906140B2 (en) * 2004-06-17 2011-03-15 Virun, Inc. Compositions for mucosal delivery of agents
US20060047025A1 (en) * 2004-06-29 2006-03-02 Matthew Piazza Viscous materials and method for producing
US7282194B2 (en) * 2004-10-05 2007-10-16 Gp Medical, Inc. Nanoparticles for protein drug delivery
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
EP3332808B1 (fr) 2005-03-03 2020-09-09 Immunomedics Inc. Anticorps humanises l243
US20090226367A1 (en) * 2005-03-11 2009-09-10 Euro-Celtique S.A. Compositions comprising an anti-ca125 antibody and a cytotoxic compound and their use for the treatment of cancer
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
NZ563392A (en) 2005-05-20 2009-12-24 Ablynx Nv Improved Nanobodies(TM) for the treatment of aggregation-mediated disorders
EP2674440B1 (fr) 2005-12-16 2019-07-03 IBC Pharmaceuticals, Inc. Ensembles bioactifs à base d'immunoglobuline multivalent
US8124598B2 (en) 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
AU2008210434C8 (en) 2007-01-31 2014-03-27 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
BRPI0809366B8 (pt) 2007-03-28 2021-05-25 Harvard College polipeptídeo substancialmente alfa-helicoidal, método para fabricação do mesmo, aminoácido e composição farmacêutica
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use
US8491890B2 (en) 2008-07-09 2013-07-23 Board Of Regents Of The University Of Nebraska Methods and compositions for inhibiting diseases of the central nervous system
AU2010254550B2 (en) * 2009-05-27 2015-10-15 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with pH sensitive release of immunomodulatory agents
AU2011258156B2 (en) 2010-05-26 2016-11-24 Selecta Biosciences, Inc. Multivalent synthetic nanocarrier vaccines
US8859723B2 (en) 2010-08-13 2014-10-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
AU2012290306B2 (en) 2011-07-29 2017-08-17 Selecta Biosciences, Inc. Synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte (CTL) immune responses
HUE045163T2 (hu) 2011-08-09 2019-12-30 Athera Biotechnologies Ab Új ellenanyagok foszforilkolin ellen
CA2843960C (fr) 2011-08-09 2020-09-15 Athera Biotechnologies Ab Anticorps aptes a se lier a la phosphorylcholine (pc) et/ou a un conjugue de pc
CN108929375A (zh) 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
CA2853138A1 (fr) 2011-12-05 2013-06-13 Immunomedics, Inc. Utilisation therapeutique d'anticorps anti-cd22 pour induire une trogocytose
US8927500B2 (en) 2012-02-15 2015-01-06 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
JP6526563B2 (ja) 2012-11-01 2019-06-05 エイルロン セラピューティクス，インコーポレイテッド 二置換アミノ酸ならびにその調製および使用の方法
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
HRP20220399T1 (hr) 2012-12-13 2022-05-13 Immunomedics, Inc. Režim doziranja imunokonjugata protutijela i sn-38 za poboljšanu učinkovitost i smanjenu toksičnost
US9107960B2 (en) 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
EP2988130A1 (fr) * 2014-08-20 2016-02-24 Eppendorf Ag Procédé de revêtement d'un support solide
SG10201902594QA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
SG11201705982PA (en) 2015-01-23 2017-08-30 Helix Biopharma Corp Antibody-urease conjugates for therapeutic purposes
MX2017011834A (es) 2015-03-20 2018-04-11 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
EP3286224A4 (fr) 2015-04-22 2018-11-14 Immunomedics, Inc. Isolement, détection, diagnostic et/ou caractérisation de cellules cancéreuses trop-2 positives
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
CA3011372A1 (fr) 2016-02-10 2017-08-17 Immunomedics, Inc. La combinaison inhibiteurs abcg2-sacituzumab govitecan (immu-132) surmonte la resistance a sn-38 dans les cancers exprimant trop-2
WO2017189279A1 (fr) 2016-04-27 2017-11-02 Immunomedics, Inc. Efficacité de conjugués médicament-anticorps anti-trop-2-sn-38 pour le traitement de tumeurs récidivantes/réfractaires à des inhibiteurs de point de contrôle
US11491114B2 (en) 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
WO2018183041A1 (fr) 2017-03-27 2018-10-04 Immunomedics, Inc. Traitement de cancer du sein triple négatif exprimant la trop-2 avec du sacmuzumab govitécan et un inhibiteur de rad51
EP3606964A4 (fr) 2017-04-03 2020-12-09 Immunomedics, Inc. Administration par voie sous-cutanée de conjugués anticorps-médicament à titre de thérapie anticancéreuse

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995631A (en) * 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US4034756A (en) * 1971-01-13 1977-07-12 Alza Corporation Osmotically driven fluid dispenser
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4320759A (en) * 1980-04-28 1982-03-23 Alza Corporation Dispenser with diffuser
US4449983A (en) * 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4925678A (en) * 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
JPS63264069A (ja) * 1987-04-22 1988-10-31 出光興産株式会社 細胞接着性材料
GB8826116D0 (en) * 1988-11-08 1988-12-14 Danbiosyst Ltd Adhesive drug delivery composition
US5320824A (en) * 1989-10-12 1994-06-14 Mallinckrodt Medical, Inc. Radionuclide labelled particles useful for radiation synovectomy
WO1992011846A1 (fr) * 1991-01-07 1992-07-23 St George's Enterprises Limited Agents particulaires
JPH05506040A (ja) * 1991-02-14 1993-09-02 バクスター、インターナショナル、インコーポレイテッド 生体接着性リポソームと標的部位との相互作用
IE921050A1 (en) * 1991-04-02 1992-10-07 Biotech Australia Pty Ltd Oral delivery systems for microparticles

Also Published As

Publication number Publication date
AU6268894A (en) 1994-09-14
JPH08507070A (ja) 1996-07-30
US5702727A (en) 1997-12-30
DE69411154T2 (de) 1998-10-22
MX9401351A (es) 1994-08-31
CA2151742A1 (fr) 1994-09-01
DE69411154D1 (de) 1998-07-23
WO1994018955A1 (fr) 1994-09-01
US5620708A (en) 1997-04-15
EP0684814B1 (fr) 1998-06-17
ATE167396T1 (de) 1998-07-15
EP0684814A1 (fr) 1995-12-06

Similar Documents

Publication Publication Date Title
CA2151742C (fr) Compositions pour l'administration d'agents actifs par voie orale
EP0740548B1 (fr) Systeme de ciblage d'un medicament, procede de preparation et utilisation de ce medicament
Tobio et al. Stealth PLA-PEG nanoparticles as protein carriers for nasal administration
CA2084194C (fr) Systeme de liberation orale pour microparticules
US7879361B2 (en) Nanoparticles for drug delivery
US7541028B2 (en) Nanoparticles for monoclonal antibody delivery
US6482413B1 (en) Vitamin B12 —biodegradable micro particulate conjugate carrier systems for peroral delivery of drugs, therapeutic peptides/proteins and vaccines
Chen et al. A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery
US7455830B2 (en) Nanoparticles for protein drug delivery
US6221397B1 (en) Surface cross-linked particles suitable for controlled delivery
US7291598B2 (en) Nanoparticles for protein drug delivery
US20030035838A1 (en) Drug delivery system exhibiting permeability control
Bhardwaj et al. Pharmaceutical aspects of polymeric nanoparticles for oral drug delivery
US7381716B2 (en) Nanoparticles for protein drug delivery
Raeisi Estabragh et al. Carrier‐Based Systems as Strategies for Oral Delivery of Therapeutic Peptides and Proteins: A Mini‐Review
AU2001242732B2 (en) Carrier systems comprising vitamin B12-biodegradable micro particulate conju gates for peroral delivery of drugs, peptides/proteins and vaccines
Silva et al. Novel chitosan-based strategies for insulin nanoencapsulation
Oyarzun-Ampuero et al. Surface-modified nanoparticles to improve drug delivery
AU2001242732A1 (en) Carrier systems comprising vitamin B12-biodegradable micro particulate conju gates for peroral delivery of drugs, peptides/proteins and vaccines
Tomlinson Site-specific drug carriers
AU9725898A (en) Drug targeting system, method for preparing same and its use
CZ2000731A3 (cs) Zesítěné částice vhodné pro aplikaci farmaceutického prostředku, způsob jejich výroby, farmaceutický prostředek, který je obsahuje a způsob jeho výroby
AU8995198A (en) Cross-linked particles
NZ517802A (en) Surface cross-linked particles suitable for controlled delivery in pharmaceutical use

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed